Eculizumab in the Treatment of Aquaporin-4 Seronegative Neuromyelitis Optica Spectrum Disorder: A Case Report

Eculizumab in the Treatment of Aquaporin-4 Seronegative Neuromyelitis Optica Spectrum Disorder: A Case Report

Objective: To report the case of a 35-year-old woman with treatment-resistant aquaporin-4 (AQP-4) immunoglobulin G (IgG) seronegative neuromyelitis optica spectrum disorder (NMOSD) successfully treated with eculizumab (a terminal complement inhibitor).Methods: The investigational procedures and trea...

Full description

Bibliographic Details
Main Authors:	Lakshmi Digala, Nakul Katyal, Naureen Narula, Raghav Govindarajan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-05-01
Series:	Frontiers in Neurology
Subjects:	autoimmune disease neuromyelitis optica spectrum disorder seronegative eculizumab aquaporin-4 complement-inactivating agents
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2021.660741/full

Similar Items

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder
by: Pratap Singh, et al.
Published: (2021-11-01)

CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder
by: Chihiro Namatame, et al.
Published: (2021-01-01)

Eculizumab‐related drug reaction in a patient with neuromyelitis optica
by: Rishi Sharma, et al.
Published: (2023-02-01)

Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder
by: Oliver Schmetzer, et al.
Published: (2021-03-01)

Association Between Helicobacter Pylori Infection and Seronegative Neuromyelitis Optica Spectrum Disorder
by: Mahdi Barzegar, et al.
Published: (2023-01-01)

Convergence spasm due to aquaporin-positive neuromyelitis optica spectrum disorder
by: Pınar Özçelik, et al.
Published: (2017-06-01)

The developmental history of study on neuromyelitis optica
by: Kai FENG, et al.
Published: (2014-09-01)

Anti-myelin Oligodendrocyte Glycoprotein in Aquaporin-4 Negative Neuromyelitis Optica Spectrum Disorder
by: Vahid Shaygannejad, et al.
Published: (2021-01-01)

Aquaporin-4 Gene Polymorphisms in Neuromyelitis Optica and Recurrent Optic Neuritis
by: Arman Çakar, et al.
Published: (2020-06-01)

Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study
by: Romain Marignier, et al.
Published: (2024-01-01)

Symptomatic narcolepsy as a presenting feature of neuromyelitis optica
by: Pradeep Kallollimath, et al.
Published: (2018-01-01)

Detection and clinical value of NMO-IgG in neuromyelitis optica
by: De-hui HUANG, et al.
Published: (2014-09-01)

Neuromyelitis optica - an update: 2007-2009
by: Jacob Anu
Published: (2009-01-01)

Seronegative Neuromyelitis Optica: A Case Report of a Hispanic Male
by: Nabeel Badri, et al.
Published: (2016-05-01)

The distribution characteristics of aquaporin 4 antibody in patients with neuromyelitis optica and the relationship between aquaporin 4 antibody and oligoclonal bands
by: Hui-cong NIU, et al.
Published: (2014-09-01)

Neuromyelitis optica
by: Jacob Anu, et al.
Published: (2007-01-01)

Syndrome of inappropriate antidiuretic hormone secretion associated with seronegative neuromyelitis optica spectrum disorder
by: Shin Ju Oh, et al.
Published: (2017-03-01)

Predominant Myofibrillar Pathology with Preserved Sarcolemmal Aquaporin 4 Immunoreactivity in a Patient with Neuromyelitis Optica-Associated HyperCKemia
by: So-Young Huh, et al.
Published: (2021-12-01)

Clinical characteristics of late ⁃ onset and very late ⁃ onset neuromyelitis optica spectrum disorders
by: ZHANG Jing, et al.
Published: (2022-09-01)

Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy
by: V. S. Krasnov, et al.
Published: (2022-12-01)

The Emerging Role of Microglia in Neuromyelitis Optica
by: Tingjun Chen, et al.
Published: (2021-02-01)

Neuromyelitis optica-IgG testing in an Indian cohort with neuromyelitis optica and related demyelinating disorders: Our experience
by: Narayanan Unni, et al.
Published: (2013-01-01)

Consensus of expert advices on routing, diagnosis, and management of patients with neuromyelitis optica spectrum disorders
by: A. N. Boyko, et al.
Published: (2021-10-01)

New advancements in the management of Neuromyelitis Optica spectrum disease: literature review
by: Padmaja Sudhakar, et al.
Published: (2023-05-01)

Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-analysis of Randomized Control Trials
by: Fanxin Kong, et al.
Published: (2021-07-01)

Therapeutic efficacy of plasma exchange in neuromyelitis optica
by: Rajesh Kumar, et al.
Published: (2018-01-01)

Autoantibodies in patients with neuromyelitis optica
by: Xin FAN, et al.
Published: (2016-10-01)

Intractable vomiting and hiccups as the presenting symptom of neuromyelitis optica
by: Girish Baburao Kulkarni, et al.
Published: (2014-01-01)

Research progress of neuromyelitis optica spectrum disorders: Chinese scholars' reports published abroad
by: Jie-xi WEN, et al.
Published: (2016-09-01)

Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies
by: Edgar Carnero Contentti, et al.
Published: (2021-09-01)

Neuromyelitis optica spectrum disorder: a pediatric case report
by: Mujgan Arslan, et al.
Published: (2017-09-01)

Clinical and brain MRI appearances in neuromyelitis optica
by: Shijuan ZHANG, et al.
Published: (2011-06-01)

The clinical characteristics of neuromyelitis optica spectrum disorders with other autoimmune diseases
by: SUN Qing⁃li, et al.
Published: (2022-04-01)

Clinical and imaging characteristics and autoantibody analysis of neuromyelitis optica spectrum disorders
by: Nan LIU, et al.
Published: (2014-09-01)

Astrocytic Interleukin-15 Reduces Pathology of Neuromyelitis Optica in Mice
by: Zhiguo Li, et al.
Published: (2018-03-01)

Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders
by: Mader Simone, et al.
Published: (2011-12-01)

The Association of Neuromyelitis Optica without Myelitis and Systemic Lupus Erythematosus: A Case Report
by: Asal Azami, et al.
Published: (2018-02-01)

Neuromyelitis optica spectrum disorder – case report
by: Grażyna Ściegienna-Zdeb, et al.
Published: (2016-04-01)

Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders
by: Leung-Wah Yick, et al.
Published: (2020-08-01)

B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders
by: Jan Traub, et al.
Published: (2021-01-01)